Objectives of study are (1) to reinforce the national capacity for diagnosis and
antibiogram of some infectious diseases causing severe acute respiratory
infection (SARI) and (2) to build a network between hospital and laboratory
for the diagnosis and surveillance of SARI in Yangon. This study is a crosssectional hospital- and laboratory-based descriptive study. A total of 825
samples including respiratory samples and blood samples from 511 children
attending Yangon Children’s Hospital and Yankin Children’s Hospital from
December 2014 to April 2016 for treatment of SARI were included.
Identification and antibiotic sensitivity testing were done using Vitek 2. Out of
129 gram-negative bacilli (GNB), K. pneumoniae 32%, P. aeruginosa 18%,
A. baumannii 13%, E. coli 9% were mostly isolated. Among 35 gram-positive
cocci (GPC), S. aureus 42% and S. pneumoniae 6% were mostly isolated.
Multidrug resistance rates were E. coli 100%, K. pneumoniae 95%, A. baumanii 82% and P. aeruginosa 17%. Extended-spectrum beta-latamase (ESBL)-producing K. pneumoniae and E. coli was 6 out of 10 tested organisms. Carbarpenemase-producing GNB and methicillin-resistant Staphylococcus aureus (MRSA) were 21% and 33%, respectively. Virology section tested 529 samples of 490 patients using the FTD33 Multiplex PCR method which can detect 33 pathogens including 20 viruses, 12 bacteria and 1 fungus. Out of 490 patients, 374 were PCR positive. Different types of samples including nasopharyngeal, throat, endotracheal and laryngeal swab, tracheal secretion and bronchoalveolar lavage, were tested. Out of 566 viruses, respiratory syncytial virus (RSV) (19.3%), rhinovirus (17.0%), parechovirus (14.3%), bocavirus (11.1%), adenovirus (10.2%), metapneumo-virus A and B (10.2%), parainfluenza virus (5.7%), enterovirus (3.0%), influenza A virus (2.8%), coronavirus (4%), parainfluenza virus (0.9%) and influenza C virus (0.4%) were detected. This study highlighted the etiological agents of bacteria, viruses and drug-resistant bacterial pathogens in SARI.
COVID-19 pre-procedural testing strategy and early outcomes at a large tertiary care children’s hospital